Affordable Access

Publisher Website

Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

Authors
Journal
Journal of Crohn s and Colitis
1873-9946
Publisher
Elsevier
Publication Date
Volume
5
Issue
6
Identifiers
DOI: 10.1016/j.crohns.2011.05.005
Keywords
  • Adalimumab
  • Crohn'S Disease
  • Weekly Dosing
  • Predictors
  • Pharmacy Claims Data
Disciplines
  • Medicine
  • Pharmacology

Abstract

Abstract Background and aims To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD). Methods Patients with CD receiving adalimumab maintenance therapy (≥ 3 dispensing events within 1 year) were identified from a large specialty pharmacy database in the United States (March 2007–July 2008). Weekly dosing rates (≥ 2 consecutive weekly doses after the first dispensing event) for a 12-month period were estimated with Kaplan–Meier methods. Predictors for weekly dosing were identified using Cox proportional-hazards regression. Results The overall adalimumab weekly dosing rate was 11.3% (151 of 1335 patients). The 12-month cumulative risk of weekly dosing was 15.5%. Patients who received a 160-/80-mg induction regimen had half the risk for weekly dosing compared with other induction regimens (hazard ratio, 0.48; 95% confidence intervals 0.33–0.7; p < 0.0001). Weekly dosing rates were significantly lower in the West and South vs. the Northeast. Conclusions The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Association of baseline C-reactive protein and pri...

on Current medical research and o... May 2013

Real-world use patterns of olanzapine long-acting...

on Current medical research and o... November 2013

Predictors of dose escalation of adalimumab in a p...

on Alimentary pharmacology & ther... February 2012

Treatment patterns with etanercept and adalimumab...

on Journal of Dermatological Trea... May 21, 2013
More articles like this..